- Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
- Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference
- Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
- Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology
- Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Arcutis Appoints David Topper as Chief Financial Officer
- Arcutis Promotes Todd Tucker to Chief Human Resources Officer
- Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
- New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
- Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
More ▼
Key statistics
As of last trade Arcutis Biotherapeutics Inc (ARQT:NSQ) traded at 10.29, -21.87% below its 52-week high of 13.17, set on Apr 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.96 |
---|---|
High | 11.19 |
Low | 9.57 |
Bid | 10.29 |
Offer | 10.30 |
Previous close | 10.49 |
Average volume | 2.80m |
---|---|
Shares outstanding | 115.76m |
Free float | 113.17m |
P/E (TTM) | -- |
Market cap | 1.21bn USD |
EPS (TTM) | -2.91 USD |
Data delayed at least 15 minutes, as of Jul 08 2024 20:09 BST.
More ▼